The Abivax stock shows an increase of 1.92% at midday this Tuesday, February 3, 2026, reaching 95.50 euros. This progress follows a week marked by a 6% decline, in a context where the French biotech benefits from enhanced prospects by several financial institutions.
The company, specialized in the development of treatments for inflammatory diseases, has recently benefited from significant reassessments by analysts. In mid-January, Stifel raised its price target from 100 to 142 euros, while reiterating its buy recommendation. This new target suggests a potential appreciation of nearly 49% compared to the current quote. At the same time, Kepler Cheuvreux also adjusted its valuation, raising its target price from 70 to 130 euros. These revisions reflect increased confidence from financial institutions in the commercial prospects of the laboratory, which has shown an exceptional stock market performance over the past year with an increase of 1,481%. However, over the last three months, the stock has shown a more moderate performance of 5.06%.
Technical Analysis Perspective
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a technical analysis standpoint, Abivax is in a delicate configuration. The RSI indicator is at 34, a level indicating an oversold zone and suggesting a possible short-term technical rebound. This measure reflects the recent correction of the stock after reaching highs at the beginning of the year. However, the moving averages confirm an underlying bullish trend: the price remains well above its 200-day moving average established at 59.79 euros. Conversely, the stock is trading below its 20 and 50-day moving averages, at 101.72 and 105.06 euros respectively, which indicates a consolidation phase. The major resistance is positioned at 122.40 euros, while the immediate support is at 93.70 euros, a level tested during the previous session. The monthly volatility of 16.22% illustrates the range of movements to which the stock remains exposed in this adjustment phase.
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
